IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease
- PMID: 21472005
- PMCID: PMC3122054
- DOI: 10.1038/cddis.2011.17
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease
Erratum in
-
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.Cell Death Dis. 2012 Aug 23;3(8):e379. doi: 10.1038/cddis.2012.123. Cell Death Dis. 2012. PMID: 22914327 Free PMC article.
Abstract
To through light on the mechanisms underlying the stimulation and persistence of glial cell activation in Parkinsonism, we investigate the function of IFN-γ and TNF-α in experimental models of Parkinson's disease and analyze their relation with local glial cell activation. It was found that IFN-γ and TNF-α remained higher over the years in the serum and CNS of chronic Parkinsonian macaques than in untreated animals, accompanied by sustained glial activation (microglia and astroglia) in the substantia nigra pars compacta. Importantly, Parkinsonian monkeys showed persistent and increasing levels of IFN-γR signaling in both microglial and astroglial cells. In addition, experiments performed in IFN-γ and TNF-α KO mice treated with MPTP revealed that, even before dopaminergic cell death can be observed, the presence of IFN-γ and TNF-α is crucial for microglial and astroglial activation, and, together, they have an important synergistic role. Both cytokines were necessary for the full level of activation to be attained in both microglial and astroglial cells. These results demonstrate that IFN-γ signaling, together with the contribution of TNF-α, have a critical and cell-specific role in stimulating and maintaining glial cell activation in Parkinsonism.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3122054/bin/cddis201117f6.gif)
Similar articles
-
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.Cell Death Dis. 2012 Aug 23;3(8):e379. doi: 10.1038/cddis.2012.123. Cell Death Dis. 2012. PMID: 22914327 Free PMC article.
-
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.Am J Pathol. 2007 Feb;170(2):680-92. doi: 10.2353/ajpath.2007.060378. Am J Pathol. 2007. PMID: 17255335 Free PMC article.
-
Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.J Neurosci. 2007 Mar 21;27(12):3328-37. doi: 10.1523/JNEUROSCI.5321-06.2007. J Neurosci. 2007. PMID: 17376993 Free PMC article.
-
Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.Toxicol Lett. 2017 Jan 4;265:30-37. doi: 10.1016/j.toxlet.2016.11.002. Epub 2016 Nov 16. Toxicol Lett. 2017. PMID: 27865851 Review.
-
Changes in cytokines and neurotrophins in Parkinson's disease.J Neural Transm Suppl. 2000;(60):277-90. doi: 10.1007/978-3-7091-6301-6_19. J Neural Transm Suppl. 2000. PMID: 11205147 Review.
Cited by
-
Astrocytes: The Stars in Neurodegeneration?Biomolecules. 2024 Feb 28;14(3):289. doi: 10.3390/biom14030289. Biomolecules. 2024. PMID: 38540709 Free PMC article. Review.
-
Phosphorylation of AQP4 by LRRK2 R1441G impairs glymphatic clearance of IFNγ and aggravates dopaminergic neurodegeneration.NPJ Parkinsons Dis. 2024 Jan 31;10(1):31. doi: 10.1038/s41531-024-00643-z. NPJ Parkinsons Dis. 2024. PMID: 38296953 Free PMC article.
-
IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy.Acta Neuropathol Commun. 2024 Jan 18;12(1):11. doi: 10.1186/s40478-023-01710-x. Acta Neuropathol Commun. 2024. PMID: 38238869 Free PMC article.
-
Oral pathogens exacerbate Parkinson's disease by promoting Th1 cell infiltration in mice.Microbiome. 2023 Nov 17;11(1):254. doi: 10.1186/s40168-023-01685-w. Microbiome. 2023. PMID: 37978405 Free PMC article.
-
Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain.Brain Behav Immun. 2023 Jul;111:277-291. doi: 10.1016/j.bbi.2023.04.008. Epub 2023 Apr 24. Brain Behav Immun. 2023. PMID: 37100211 Free PMC article.
References
-
- McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285–1291. - PubMed
-
- Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW. Astrocytes and Parkinson's disease. Prog Brain Res. 1992;94:429–436. - PubMed
-
- Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598–605. - PubMed
-
- McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol. 2003;54:599–604. - PubMed
-
- Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, et al. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1 year after MPTP exposure. Glia. 2004;46:402–409. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous